Humacyte: director D. Scott Coward received 125,000 shares

What happened D. Scott Coward, a director of Humacyte, received an award of 125,000 derivative shares on Oct 6, 2026, at $0.00 per share (total $0.00), reported on a Form 4 filed Oct 7, 2026.

Key details

• Transaction date and price: Oct 6, 2026 — award of 125,000 derivative shares at $0.00 per share.
• Filing date: Oct 7, 2026.
• Shares owned after the transaction: not reported in the Form 4 provided.
• Footnote (F1): The first 25% of the option becomes exercisable on Oct 6, 2027; thereafter 1/48 of the option becomes exercisable on the 6th day of each month, with full vesting on Oct 6, 2030.
• Transaction code: A (award/grant or other acquisition, derivative).

Why it may matter

• This filing reports a grant of derivative securities (an option award) with a multi-year vesting schedule, not an exercised sale or market trade.
  A filing does not show why the insider traded or why the company acted.